Comprehensive Evaluation of Alternative API, Excipient, and Packaging Material Sources: A Regulatory Perspective

Incorporating alternative sources for Active Pharmaceutical Ingredients (API), excipients, and primary packaging materials in approved pharmaceutical products necessitates rigorous evaluation to ensure product quality, safety, and efficacy are maintained. Regulatory agencies, including the World Health Organization (WHO), the United States Food and Drug Administration (US FDA), the European Medicines Agency (EMA), and the UK Medicines and Healthcare products Regulatory Agency (UK MHRA), require comprehensive data to assess such changes. This abstract summarizes the key data requirements across these agencies, focusing on API, excipients, and primary packaging materials. For APIs, critical data include comparative analytical testing, impurity profiling, stability studies under ICH conditions, and bioequivalence studies when applicable. Agencies mandate risk assessments and process validation to ensure the new API source does not compromise the product's critical quality attributes (CQAs) or therapeutic performance. For excipients, regulatory bodies require detailed information on the new supplier’s compliance with Good Manufacturing Practices (GMP), certificate of analysis (CoA), and comparative studies to demonstrate equivalence in performance, stability, and compatibility with the drug product. Stability testing, extractables and leachables analysis, and risk assessment play crucial roles in ensuring the excipient change does not negatively impact product quality or patient safety. Primary packaging material changes require a thorough evaluation of mechanical and barrier properties, container-closure integrity (CCI), and extractables and leachables studies. Stability testing with the new packaging material under ICH conditions, risk assessments, and functional equivalence testing are essential to confirm the packaging material’s suitability in protecting the drug product throughout its shelf life. In conclusion, stringent regulatory expectations underscore the importance of comprehensive data generation and risk mitigation strategies when incorporating alternative sources for APIs, excipients, and packaging materials in pharmaceutical products. Adherence to these guidelines ensures product safety, efficacy, and compliance with global regulatory standards.在已获批的药品中采用活性药物成分（Active Pharmaceutical Ingredients，API）、药用辅料（excipients）以及内包装材料（primary packaging materials）的替代来源时，需开展严格的评估工作，以确保产品的质量、安全性与有效性得以维持。包括世界卫生组织（World Health Organization，WHO）、美国食品药品监督管理局（United States Food and Drug Administration，US FDA）、欧洲药品管理局（European Medicines Agency，EMA）以及英国药品与医疗保健产品监管署（UK Medicines and Healthcare products Regulatory Agency，UK MHRA）在内的监管机构，均要求提供全面的数据以评估此类变更。本摘要概述了上述各监管机构针对此类变更的关键数据要求，重点围绕活性药物成分、药用辅料及内包装材料展开。对于活性药物成分而言，关键数据包括对比分析测试、杂质谱分析、符合国际人用药品注册技术协调会（ICH）指导原则的稳定性研究，以及适用情况下的生物等效性研究。各监管机构均要求开展风险评估与工艺验证，以确保新的活性药物成分来源不会损害产品的关键质量属性（critical quality attributes，CQAs）或治疗性能。对于药用辅料而言，监管机构要求提供新供应商符合药品生产质量管理规范（Good Manufacturing Practices，GMP）的相关信息、分析证明书（certificate of analysis，CoA），以及用于证明其在性能、稳定性及与药品配伍性方面等效性的对比研究数据。稳定性测试、可提取物与浸出物分析以及风险评估，对于确保药用辅料变更不会对产品质量或患者安全造成负面影响至关重要。内包装材料变更需对其机械性能、阻隔性能、容器密闭完整性（container-closure integrity，CCI）以及可提取物与浸出物开展全面评估。采用新型包装材料开展的符合国际人用药品注册技术协调会（ICH）指导原则的稳定性测试、风险评估以及功能等效性测试，对于确认该包装材料在药品整个货架期内的防护适用性至关重要。综上，严格的监管要求凸显了在药品中采用活性药物成分、药用辅料及包装材料的替代来源时，开展全面数据生成与风险缓解策略的重要性。遵循这些指南可确保产品的安全性、有效性，并符合全球监管标准。